Abstract
Approximately one-fifth of the NA-treated CHB patients with advanced liver fibrosis and compensated cirrhosis experienced progression of liver fibrosis after PEG-IFN α-2a treatment. The GPR at 24 weeks of treatment was an independent predictive factor for the progression of liver fibrosis in this population.
Affiliated Institutions
Related Publications
Efficacy and Safety of Pegylated (40–Kd) Interferon α–2A Compared With Interferon α–2A in Noncirrhotic Patients With Chronic Hepatitis C
Administration of interferon (IFN) 3 times weekly in patients with chronic hepatitis C (CHC) is associated with low sustained responses, which may be, in part, related to this r...
Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis
In patients with chronic hepatitis C and cirrhosis or bridging fibrosis, 180 microg of peginterferon alfa-2a administered once weekly is significantly more effective than 3 mill...
Update on prevention, diagnosis, and treatment of chronic hepatitis B
Potential conflict of interest: Dr. Hwang received grants from Merck and Gilead. Dr. Chang advises Arbutus. Dr. Lok received grants from Gilead and Bristol‐Myers Squibb. Dr. Jon...
Natural history of nonalcoholic steatohepatitis: A longitudinal study of repeat liver biopsies
Nonalcoholic steatohepatitis may cause severe fibrosis, cirrhosis, and hepatocellular carcinoma, but supporting evidence is based on indirect data. Few publications have examine...
Impact of obesity on treatment of chronic hepatitis C†
Obesity and the metabolic syndrome have hepatic manifestations, including steatosis and progression of fibrosis. In individuals with chronic hepatitis C, obesity is associated w...
Publication Info
- Year
- 2025
- Type
- article
- Citations
- 0
- Access
- Closed
External Links
Social Impact
Social media, news, blog, policy document mentions
Citation Metrics
Cite This
Identifiers
- DOI
- 10.1186/s12876-025-04508-4